腾盛博药-B(02137)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02137 腾盛博药-B

已收盘 10-15 16:08:33

0.850

+0.015

+1.80%

最高0.860	最低0.815	成交量56.55万
今开0.840	昨收0.835	日振幅5.39%
总市值6.14亿	流通市值6.14亿	总股本7.22亿
成交额47.45万	换手率0.08%	流通股本7.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02137","market":"HK","secType":"STK","nameCN":"腾盛博药-B","latestPrice":0.85,"timestamp":1792051713439,"preClose":0.835,"halted":0,"volume":565500,"delay":0,"changeRate":0.017964071856287442,"floatShares":722000000,"shares":722000000,"eps":-0.36173696372268216,"marketStatus":"已收盘","change":0.015,"latestTime":"10-15 16:08:33","open":0.84,"high":0.86,"low":0.815,"amount":474480,"amplitude":0.053892,"askPrice":0.855,"askSize":55500,"bidPrice":0.85,"bidSize":14000,"shortable":0,"etf":0,"ttmEps":-0.28242618398399183,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792114200000},"marketStatusCode":5,"adr":0,"listingDate":1626105600000,"exchange":"SEHK","adjPreClose":0.835,"openAndCloseTimeList":[[1792027800000,1792036800000],[1792040400000,1792051200000]],"volumeRatio":0.958881,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02137/wiki","defaultTab":"wiki","newsList":[{"id":"2675584496","title":"腾盛博药－Ｂ：推出双特异性小干扰核糖核酸药物研发平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2675584496","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675584496?lang=zh_cn&edition=full","pubTime":"2026-10-15 19:37","pubTimestamp":1792064243,"startTime":"0","endTime":"0","summary":"南财智讯10月15日电，腾盛博药－Ｂ（02137.HK）发布自愿公告，公司董事会宣布推出自主研发的双特异性核糖核酸干扰沉默小干扰核糖核酸药物研发平台，以推动下一代核糖核酸疗法的研发。该平台融合序列优化、化学修饰、双靶点设计和靶向递送四大核心技术模块，旨在提升小干扰核糖核酸药物的选择性、药效表现及治疗潜力。目前，该平台已应用于多个内部研发项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610153897098596.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610153897098596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBJ","02137","BK1587","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675581861","title":"腾盛博药-B(02137.HK)宣布推出BRiSC™ siRNA药物研发平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2675581861","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675581861?lang=zh_cn&edition=full","pubTime":"2026-10-15 19:33","pubTimestamp":1792063997,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1587","BK1161","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675502023","title":"腾盛博药-B(02137.HK)10月13日斥资9.3万港元回购11万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675502023","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675502023?lang=zh_cn&edition=full","pubTime":"2026-10-13 22:15","pubTimestamp":1791900954,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02137","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149330432","title":"腾盛博药-B回购11万股，涉资约9.30万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149330432","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149330432?lang=zh_cn&edition=full","pubTime":"2026-10-13 22:15","pubTimestamp":1791900953,"startTime":"0","endTime":"0","summary":"腾盛博药-B（股票代码：02137）于2026年10月13日在香港联交所回购股份，数量为110,000股，占回购前已发行股本约0.0152%。每股回购价格为0.845港元，合计支付价格约92,950港元（即约9.30万港元）。回购完成后，公司已发行股份数量减少至721,949,132股，库藏股数量增至13,371,500股。\n本次回购所依据的购回授权通过日期为2026年6月16日，公司在此之前于包含本次在内的回购活动中已合计回购了648,000股。公司确认，其回购事宜符合香港联交所证券上市规则及相关监管要求。\n公告由联席公司秘书李安康博士签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"腾盛博药-B回购11万股，涉资约9.30万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674038288","title":"腾盛博药-B(02137.HK)10月12日斥资9.12万港元回购10.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2674038288","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674038288?lang=zh_cn&edition=full","pubTime":"2026-10-12 21:39","pubTimestamp":1791812390,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1587","02137","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157385677","title":"腾盛博药-B10月12日回购10.70万股，耗资约9.12万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157385677","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157385677?lang=zh_cn&edition=full","pubTime":"2026-10-12 21:36","pubTimestamp":1791812171,"startTime":"0","endTime":"0","summary":"腾盛博药生物科技有限公司于2026年10月12日发布翌日披露报表，公告当日回购普通股10.70万股，约占该次回购前已发行股本0.0148%。每股回购价范围介乎港币0.84元至0.865元，合计耗资约港币9.12万元。本次回购完成后，公司已发行股本为722,059,132股，库藏股增加至13,261,500股，总股本仍为735,320,632股。腾盛博药-B在公告中重申已遵守香港联合交易所有限公司证券上市规则等相关法律规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"腾盛博药-B10月12日回购10.70万股，耗资约9.12万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674685728","title":"腾盛博药-B(02137.HK)10月9日斥资8.5万港元回购10.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2674685728","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674685728?lang=zh_cn&edition=full","pubTime":"2026-10-09 22:02","pubTimestamp":1791554542,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02137","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136952401","title":"腾盛博药-B回购10.1万股股份，耗资约8.50万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136952401","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136952401?lang=zh_cn&edition=full","pubTime":"2026-10-09 22:01","pubTimestamp":1791554468,"startTime":"0","endTime":"0","summary":"2026年10月9日，腾盛博药生物科技有限公司公布翌日披露报表。公告显示，公司于当日于香港联交所场内回购股份10.1万股，占回购前已发行股本约0.014%，每股回购价介乎0.825港元至0.86港元，合计涉资约8.50万港元。公司同日根据2023年9月1日采纳的2023股份奖励计划，为公司员工发行并配发5,875股新股，占回购前已发行股本约0.0008%。根据本次变动，腾盛博药-B于2026年10月9日收市后，已发行股本总数由735,314,757股增至735,320,632股，其中已发行股份为722,166,132股，库藏股数增至13,154,500股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"腾盛博药-B回购10.1万股股份，耗资约8.50万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673958003","title":"腾盛博药-B(02137)授出合共725.8万份购股权及授出合共138.95万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2673958003","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673958003?lang=zh_cn&edition=full","pubTime":"2026-10-08 22:11","pubTimestamp":1791468668,"startTime":"0","endTime":"0","summary":"腾盛博药-B(02137)发布公告，于2026年10月8日，本公司根据2023年购股权计划条款向63名购股权受让人授出合共725.8万份购股权，惟须待购股权受让人接纳。于本公告日期，已发行股份总数为7.22亿股(不包括库存股)。根据授出购股权授出的该等购股权获悉数行使后，据此将配发及发行的股份占本公告日期已发行股份总数(不包括库存股)约1.0%及经扩大已发行股份总数约1.0%(不包括库存股及根据授出受限制股份单位授予受限制股份单位受让人的任何受限制股份单位的归属情况)。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggaonew/ganggugongg27.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggaonew/ganggugongg27.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02137","BK1574","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121371227","title":"腾盛博药-B（02137）授出725.8万份购股权及138.95万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=1121371227","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121371227?lang=zh_cn&edition=full","pubTime":"2026-10-08 22:05","pubTimestamp":1791468334,"startTime":"0","endTime":"0","summary":"10月8日，腾盛博药-B公告称，董事会已根据2023年购股权计划及2023年股份奖励计划，向员工授出合共7,258,000份购股权及1,389,500份受限制股份单位。授出对象：63名集团员工，包括2名执行董事、4名高级管理人员及57名其他员工。总数量：7,258,000份购股权，相当于截至公告日已发行股份总数722,261,257股的约1.0%，占经扩大后已发行股份总数的约1.0%。代价：每名受让人接纳购股权需支付1.00港元。交易所独立非执行董事已审阅并批准向两名执行董事授予的权益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195269770","title":"腾盛博药-B发布9月股份变动月报表，股本规模小幅增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1195269770","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195269770?lang=zh_cn&edition=full","pubTime":"2026-10-07 17:30","pubTimestamp":1791365451,"startTime":"0","endTime":"0","summary":"腾盛博药生物科技有限公司于2026年10月7日发布截至2026年9月30日的证券变动月报。报告期内，注册股本未发生变动，仍为1,200,000,000股普通股，对应法定股本6,000美元。报告显示，公司于报告期内根据首次公开发售后股份奖励计划新增发行356,517股普通股，并通过该计划转让了291,375股库存股份。本月报披露，截至2026年9月30日，公司已经满足香港联合交易所有限公司的公众持股量要求，整体股本结构保持稳定，股权分配符合上市规则和相关法律法规的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188227323","title":"创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188227323","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188227323?lang=zh_cn&edition=full","pubTime":"2026-09-23 11:01","pubTimestamp":1790132509,"startTime":"0","endTime":"0","summary":"9月23日，创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%，康方生物、诺诚健华涨逾3%，基石药业涨逾2%，百济神州、药明生物、君实生物涨逾1%，信达生物跟涨。9月12-15日2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3 ADC等成为焦点；与此同时，2026年国家医保目录谈判收官，商保创新药目录同步推进，支付端改革预期升温，\"出海商业化+支付改善\"的产业逻辑持续强化。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","06978","06606","09606","09688","09966","09995","06996","01801","02359","02137","03347","02269","06618","01672","00241","06622","03759"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2669141461","title":"克来机电：9月21日严立忠、曹卫红、李南增持股份合计101.23万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141461","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669141461?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:02","pubTimestamp":1790078523,"startTime":"0","endTime":"0","summary":"证券之星消息，根据9月22日市场公开信息、上市公司公告及交易所披露数据整理，克来机电最新董监高及相关人员股份变动情况：2026年9月21日公司高级管理人员严立忠、董事曹卫红、高级管理人员李南共增持公司股份101.23万股，占公司总股本为0.3861%。变动期间公司股价上涨7.24%，9月21日当日收盘报18.36元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200037128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","603960","BK0130","02137","BK1574","BK1161","BK1587","BK0061","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167351567","title":"腾盛博药生物科技有限公司因股份奖励归属增发285,375股，涉已发行股本变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1167351567","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167351567?lang=zh_cn&edition=full","pubTime":"2026-09-21 21:46","pubTimestamp":1789998382,"startTime":"0","endTime":"0","summary":"腾盛博药生物科技有限公司于2026年9月21日发布公告，宣布已发行股本发生变动。本次变动源于根据该公司于2021年6月22日采纳的首次公开发售后股份奖励计划，向公司董事授出受限制股份单位并相应增发股份。本次增发285,375股普通股，占本次增发前公司已发行股本约0.0395%，每股发行价为0港元。完成后，公司已发行股本增至722,190,115股，库藏股维持13,053,500股，合计735,243,615股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"腾盛博药生物科技有限公司因股份奖励归属增发285,375股，涉已发行股本变动","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669693021","title":"腾盛博药-B(02137)因受限制股份单位获归属而发行28.54万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669693021","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669693021?lang=zh_cn&edition=full","pubTime":"2026-09-21 21:44","pubTimestamp":1789998285,"startTime":"0","endTime":"0","summary":"智通财经APP讯，腾盛博药-B(02137)发布公告，于2026年9月21日因根据公司于2021年6月22日采纳的首次公开发售后股份奖励计划授出的受限制股份单位归属，而向公司董事发行及配发28.54万股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499002.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK1587","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669163613","title":"克来机电：9月18日曹卫红、严立忠增持股份合计72万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669163613","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669163613?lang=zh_cn&edition=full","pubTime":"2026-09-21 20:01","pubTimestamp":1789992111,"startTime":"0","endTime":"0","summary":"证券之星消息，根据9月21日市场公开信息、上市公司公告及交易所披露数据整理，克来机电最新董监高及相关人员股份变动情况：2026年9月18日公司董事曹卫红、高级管理人员严立忠共增持公司股份72.0万股，占公司总股本为0.2746%。变动期间公司股价上涨0.71%，9月18日当日收盘报17.12元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100028829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1587","BK0061","BK1161","BK0020","BK0130","BK1574","02137","603960","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140454541","title":"腾盛博药-B：9月18日回购3万股，耗资约2.58万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1140454541","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140454541?lang=zh_cn&edition=full","pubTime":"2026-09-18 20:16","pubTimestamp":1789733797,"startTime":"0","endTime":"0","summary":"腾盛博药-B于2026年9月18日发布翌日披露报表。公告显示，公司当日于香港联交所场内回购普通股30,000股，约占回购前已发行股份总数的0.0042%。回购价格每股为0.86港元，合计支出25,800港元。公司购回授权于2026年6月16日获股东大会批准，总回购额度为72,185,205股，现已累计回购330,000股，剩余额度为72,185,205股减去330,000股。公司同时确认，本次回购符合香港联交所证券上市规则及其他相关法规。本公告由联席公司秘书李安康博士签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"腾盛博药-B：9月18日回购3万股，耗资约2.58万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668260923","title":"腾盛博药-B(02137)9月18日斥资2.58万港元回购3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2668260923","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668260923?lang=zh_cn&edition=full","pubTime":"2026-09-18 20:12","pubTimestamp":1789733576,"startTime":"0","endTime":"0","summary":"智通财经APP讯，腾盛博药-B(02137)发布公告，于2026年9月18日，该公司斥资2.58万港元回购3万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","02137","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111390125","title":"腾盛博药-B2026年中期营收1,952.10万元，经调整净亏损9,606.40万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111390125","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111390125?lang=zh_cn&edition=full","pubTime":"2026-09-17 16:37","pubTimestamp":1789634248,"startTime":"0","endTime":"0","summary":"本季度信息\n财报显示，腾盛博药-B在2026年上半年录得营收约1,952.10万元，同比去年同期的2,812.70万元下降30.56%。同期，经调整净亏损为9,606.40万元，相比去年同期的14,658.70万元减少约34.47%，亏损幅度明显收窄。\n公司在成本端持续优化研发及管理支出。研发投入为9,833.20万元，相较去年同期的11,702.00万元下降15.97%，管理费用为5,257.60万元，同比减少9.70%。经营活动所用现金净流出为16,548.80万元，相比上年同期22,137.60万元减少25.24%，显示整体经营资金消耗进一步得到改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"腾盛博药-B2026年中期营收1,952.10万元，经调整净亏损9,606.40万元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667988061","title":"克来机电：9月15日高级管理人员严立忠、李南增持股份合计90万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667988061","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667988061?lang=zh_cn&edition=full","pubTime":"2026-09-16 20:01","pubTimestamp":1789560117,"startTime":"0","endTime":"0","summary":"证券之星消息，根据9月16日市场公开信息、上市公司公告及交易所披露数据整理，克来机电最新董监高及相关人员股份变动情况：2026年9月15日公司高级管理人员严立忠、高级管理人员李南共增持公司股份90.0万股，占公司总股本为0.3432%。变动期间公司股价上涨0.38%，9月15日当日收盘报15.71元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600033650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02137","BK1587","BK0061","BK1161","603960","BK1574","BK0130","BK0020","BK0251"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.briibio.com","stockEarnings":[{"period":"1week","weight":-0.0402},{"period":"1month","weight":-0.0511},{"period":"3month","weight":-0.2048},{"period":"6month","weight":-0.4433},{"period":"1year","weight":-0.5605},{"period":"ytd","weight":-0.4078}],"compareEarnings":[{"period":"1week","weight":0.0076},{"period":"1month","weight":-0.0242},{"period":"3month","weight":-0.0278},{"period":"6month","weight":-0.0706},{"period":"1year","weight":-0.0443},{"period":"ytd","weight":-0.0514}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"腾盛博药生物科技有限公司是一家主要从事感染性疾病以及中枢神经系统疾病治疗方法开发的生物科技公司。该公司研发的产品主要包括乙型肝炎病（HBV）免疫治疗候选药物BRII-179、靶向乙型肝炎表面抗原（HBsAg）的研究性HBV中和单克隆抗体Tobevibart、以及用于治疗多重耐药性（MDR）和广泛耐药性（XDR）的革兰氏阴性菌感染的合成脂肽soralimixin（BRII-693）等。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.040695},{"month":2,"riseRate":0.6,"avgChangeRate":0.049398},{"month":3,"riseRate":0.2,"avgChangeRate":-0.163076},{"month":4,"riseRate":0.2,"avgChangeRate":-0.015797},{"month":5,"riseRate":0,"avgChangeRate":-0.081235},{"month":6,"riseRate":0.2,"avgChangeRate":-0.107834},{"month":7,"riseRate":0.8,"avgChangeRate":0.07356},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.000001},{"month":9,"riseRate":0.5,"avgChangeRate":-0.011255},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.112324},{"month":11,"riseRate":0.6,"avgChangeRate":0.286305},{"month":12,"riseRate":0.2,"avgChangeRate":-0.154392}],"exchange":"SEHK","name":"腾盛博药-B","nameEN":"BRII-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"腾盛博药-B(02137)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供腾盛博药-B(02137)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"腾盛博药-B,02137,腾盛博药-B股票,腾盛博药-B股票老虎,腾盛博药-B股票老虎国际,腾盛博药-B行情,腾盛博药-B股票行情,腾盛博药-B股价,腾盛博药-B股市,腾盛博药-B股票价格,腾盛博药-B股票交易,腾盛博药-B股票购买,腾盛博药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"腾盛博药-B(02137)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供腾盛博药-B(02137)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}